Annovis Bio, Inc. is a clinical stage, drug platform company. The Company is focused on addressing neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is engaged in developing drugs that normalize the transport of information within and between nerve cells, called axonal transport. Its lead product pipelines are ANVS-401, which include ANVS-401 for AD, ANVS-401 for AD-DS, ANVS-401 for PD; ANVS-405 and ANVS-301. Its ANVS-401 restores axonal transport and homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. The Company is in an ongoing Phase II A proof-of-concept study in mild to moderate AD patients and a ready program to conduct a second Phase II A study in PD patients. The Company has also developed compound to treat acute neurodegeneration traumatic brain injury (TBI) and stroke.